Global Biopharma Financing Roundup (April 7–13, 2025): Advances in Regenerative Medicine, AI Imaging, and Precision Therapeutics

1. iRegene

• Round and Amount:B+Raised nearly 100 million yuan in a round of financing, led by Fengchuan Capital and followed by Hetang Ventures.

• Technical Direction: Regenerative Medicine, Advancing Parkinson's Disease and Ophthalmic Cell Therapy Products in Clinical Trials in China and the United States.

  
  

2. Weican Medical

• Round and Amount: Tens of millions of yuan in angel financing, jointly led by Yuanhe Origin and Nuoyu Capital, with Nanjing Jiangbei Science and Technology Investment following up.

• Technical Direction: Minimally Invasive Implantable Drug Delivery Devices (PORT) Research and Development.

  
  

3. Zhongsheng Traceability

• Round and Amount:B+Rounds of financing amounting to tens of millions of RMB (BWheel Accumulation2.35100 million RMB), jointly invested by Guangyao Capital, Kejin Holdings, Hefei Industrial Investment, and Hanyuan Assets.

• Technical Direction:iPSCDevelopment of Derived Cell Therapy Products.

  
  

4. Saiyun Biotechnology

• Round and Amount: Angel+Raised tens of millions in a round of financing, exclusively invested by Zhongke Innovation Star.

• Technical Direction: Targeted Delivery Technology and Innovative Drug Therapies.

  
  

5. Mitoke Bio

• Round and Amount:Pre-ARaised tens of millions in its round of financing, led by Qinzhi Capital.

• Technical Direction: Research and Development of Pet Stem Cell Drugs and Clinical Transformation.

  
  

6. Yinghe Medical

• Round and Amount:ARound financing exceeded1Million yuan, led by Yuan Yi Capital, with strategic support from funds such as Dingrun Jiade and Kezhi Chuang'an.

• Technical Direction: Medical ImagingAIBase model and industrialization.

  
  

7. Yun Shida Healthcare

• Round and Amount: Strategic Financing3500Million USD, the investor is undisclosed.

• Technical Direction: Research and Development of New Technologies in the Field of Assisted Reproductive Medicine, Intelligent Upgrading.

  
  

8. Ocumind Medical

• Round and Amount:ARaised tens of millions of RMB in a round of financing, led by Unity Venture Capital, with Chengshu Fenghua following up on the investment, and existing shareholder Haibang Fenghua adding to their investment.

• Technical Direction: Commercialization Progress and Academic Promotion of Flexible Endoscope Systems in China and Abroad, and Product Portfolio Development.

  
  

9. Xuanjing Biotechnology

• Round and Amount：Pre-ARound financing (first closing), invested by Jinyifu Xin and others.

• Technical Direction: Small nucleic acid drug research and development, promoting complementC3TargetsiRNADrugRG002C0106Clinical and Extrahepatic Delivery Technology Development.

Foreign enterprises

1. Imbria Pharmaceuticals(United States)

• Round and Amount：BRound of Financing5750Million US dollars, byDeep Track CapitalLead investment,RA Capital、SV Health InvestorsAnd other follow-up investments.

• Technical Direction: Development of Cardiometabolic Disease Therapies, Advancing Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) of2bPhase Clinical Trial.

2. Solu Therapeutics(United States)

• Round and Amount:ARound of Financing4100Million USD, Lilly,Biovision Ventures、Pappas CapitalParticipated, etc.

• Technical Direction: Small Molecules-Antibody-Drug Conjugates (CYTAC) Treatment of Hematological Tumors, InitiationIPhase Clinical Trial.

3. Merida Biosciences(United States)

• Round and Amount:ARound Financing1.21Billion USD, byBain Capital Life Sciences、BVF PartnersAndThird Rock VenturesCo-led the investment.

• Technical Direction：FcTherapy Platform for Clearing Pathogenic Antibodies andBCells, for the treatment of Graves' disease, allergies, and other autoimmune diseases.

4. Caris Life Sciences(United States)

• Round and Amount: Financing1.68Billion USD, byBraidwell LPLeading investment,Perceptive Advisors、WoodlineIncluding follow-on investments.

• Technical Direction: For the expansion of genomic testing platforms.

Summary

• Hot Topics in China: Regenerative Medicine (iRegene),iPSCCell Therapy (Anhui Zhongsheng Traceability Biotechnology Co., Ltd.) and Medical ImagingAI(Shadow禾 Medical Pulse) takes the lead, with minimally invasive devices (Weican Medical), assisted reproduction (Yunshida Medical), and small nucleic acid drugs (Xuanjing Biotech) accelerating their布局.

• International Focus: Cardiometabolic Therapy (Imbria), novel antibody-drug conjugate technology (Solu）and autoimmune diseasesFcTherapy (Merida) as the core; genomic testing (Caris) Expanding the boundaries of precision medicine.
  

• Trend：AI, Gene/Cell Therapy and Precision Instruments Drive Innovation, with Capital from China and Abroad Continuously Investing in Clinical Translation and Unmet Needs.